Akari Therapeutics (AKTX) Receivables (2011 - 2013)

Akari Therapeutics (AKTX) has 3 years of Receivables data on file, last reported at $6000.0 in Q4 2013.

• For the quarter ending Q4 2013, Receivables fell 50.0% year-over-year to $6000.0; the trailing twelve-month figure through Dec 2013 stood at $6000.0 (down 50.0% YoY), and the FY2013 full-year result was $6000.0, down 50.0% from the prior year.
• Receivables eased to $6000.0 in Q4 2013, from $12000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $19000.0 in Q4 2011 to a low of $6000.0 in Q4 2013.
• A 3-year average of $12333.3 and a median of $12000.0 in 2012 frame the typical range for Receivables.
• Across the five-year window, Receivables tumbled 36.84% in 2012 and slumped 50.0% in 2013, its largest moves.
• Tracing AKTX's Receivables over 3 years: stood at $19000.0 in 2011, then slumped by 36.84% to $12000.0 in 2012, then tumbled by 50.0% to $6000.0 in 2013.
• Business Quant data shows AKTX's Receivables at $6000.0 in Q4 2013, $12000.0 in Q4 2012, and $19000.0 in Q4 2011.